Core Viewpoint - Corning Jereh Pharmaceutical-B (09966) has seen a stock increase of over 4%, currently trading at 12.54 HKD, with a transaction volume of 43.1641 million HKD, following the acceptance of its new drug application for KN026 by the National Medical Products Administration (NMPA) [1] Group 1: Company Developments - The new drug application (NDA) for KN026, a monoclonal antibody injection developed in collaboration with Shanghai Jinmant Biotech Co., Ltd., has been accepted by NMPA [1] - KN026 is being submitted as a Class 1 new drug for therapeutic biological products, targeting HER2-positive locally advanced, recurrent, or metastatic gastric/gastroesophageal junction adenocarcinoma that has failed at least one systemic treatment including trastuzumab [1] - KN026 is the first HER2 bispecific antibody drug in China to achieve positive results in the second-line treatment of gastric cancer, addressing a gap in approved anti-HER2 drugs for this indication [1] Group 2: Clinical Research Progress - Multiple key Phase III clinical studies for KN026 in gastric and breast cancer indications are currently progressing smoothly, with the potential to benefit more patients [1]
港股异动 | 康宁杰瑞制药-B(09966)涨超4% 此前宣布KN026新药上市申请获国家药监局受理